retatrutide long term CutKilo | Retatrutide Side Effects: What Patients

Description

New England Journal of Medicine, 387(3), 205216.

Trial averages showed 24.2% body weight loss at 48 weeks on the 12mg dose, but individual results ranged from 10% to over 30%

Retatrutide is an investigational injectable triple agonist targeting GLP-1, GIP, and glucagon receptors, currently in clinical trials for obesity and type 2 diabetes but not yet approved by the MHRA or EMA

Moreover, one could imagine that retatrutide like, e.g., amphetamine (Neumann et al

Understanding GLP-1 Medications GLP-1 (glucagon-like peptide-1) medications are a revolutionary approach in the fight against insulin resistance-based weight problems